The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

被引：579

作者：

Janjigian, Yelena Y. ^{[1
,2
]}

Kawazoe, Akihito ^{[3
]}

Yanez, Patricio ^{[4
]}

Li, Ning ^{[5
]}

Lonardi, Sara ^{[6
]}

Kolesnik, Oleksii ^{[7
]}

Barajas, Olga ^{[8
]}

Bai, Yuxian ^{[9
]}

Shen, Lin ^{[10
]}

Tang, Yong ^{[11
]}

Wyrwicz, Lucjan S. ^{[12
]}

Xu, Jianming ^{[13
]}

Shitara, Kohei ^{[3
]}

Qin, Shukui ^{[14
]}

Van Cutsem, Eric ^{[15
,16
]}

Tabernero, Josep ^{[17
,18
]}

Li, Lie ^{[19
]}

Shah, Sukrut ^{[19
]}

Bhagia, Pooja ^{[19
]}

Chung, Hyun Cheol ^{[20
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Weill Cornea Med Coll, New York, NY 10065 USA

[3] Natl Canc Hosp East, Kashiwa, Chiba, Japan

[4] Univ La Frontera, James Lind Canc Res Ctr, Temuco, Chile

[5] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China

[6] Ist OncoL Veneto IOV IRCCS, Padua, Italy

[7] Med Ctr Oncolife, Zaporizhzhia, Ukraine

[8] Arturo Lopez Perez Fdn, Santiago, Chile

[9] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China

[10] Peking Univ, Minist Educ Beijing, Key Lab Carcinogenesis & TransLat Res, Dept Gastrointestinal Oncol,Canc Hosp & Inst, Beijing, Peoples R China

[11] Xinjiang Med Univ, Canc Hosp, Urumqi, Xinjiang, Peoples R China

[12] Maria Sklodowska Curie Natl Canc Res Inst, Warsaw, Poland

[13] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China

[14] Canc Ctr Peoples Liberat Army, Nanjing, Peoples R China

[15] Univ Hosp Gasthuisberg, Leuven, Belgium

[16] Katholieke Univ Leuven, Leuven, Belgium

[17] Vall dHebron Hosp Campus, Barcelona, Spain

[18] UVic UCC, Inst Oncol VH10, IOB Quiron, Barcelona, Spain

[19] Merck & Co Inc, Kenilworth, NJ USA

[20] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea

来源：

NATURE | 2021年 / 600卷 / 7890期

基金：

美国国家卫生研究院;

关键词：

NIVOLUMAB PLUS CHEMOTHERAPY; GASTROESOPHAGEAL JUNCTION; RESPONSE CRITERIA; OPEN-LABEL; TRASTUZUMAB; ESOPHAGEAL; THERAPY;

D O I：

10.1038/s41586-021-04161-3

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Human epidermal growth factor receptor 2 (HER2, also known as ERBB2) amplification or overexpression occurs in approximately 20% of advanced gastric or gastro-oesophageal junction adenocarcinomas(1-3). More than a decade ago, combination therapy with the anti-HER2 antibody trastuzumab and chemotherapy became the standard first-line treatment for patients with these types of tumours(4). Although adding the anti-programmed death 1 (PD-1) antibody pembrolizumab to chemotherapy does not significantly improve efficacy in advanced HER2-negative gastric cancer(5), there are preclinical(6-19) and clinical(20,21) rationales for adding pembrolizumab in HER2-positive disease. Here we describe results of the protocol-specified first interim analysis of the randomized, double-blind, placebo-controlled phase III KEYNOTE-811 study of pembrolizumab plustrastuzumab and chemotherapy for unresectable or metastatic, HER2-positive gastric or gastro-oesophageal junction adenocarcinoma 22 (https://clinicaltrials.gov, NCT03615326). We show that adding pembrolizumab to trastuzumab and chemotherapy markedly reduces tumour size, induces complete responses in some participants, and significantly improves objective response rate.

引用

页码：727 / +

页数：16

共 32 条

[1] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[2]

Bang YJ, 2010, LANCET, V376, P1302

[3] Resistance to Checkpoint Inhibition in Cancer Immunotherapy [J].

Barrueto, Luisa ;

Caminero, Francheska ;

Cash, Lindsay ;

Makris, Courtney ;

Lamichhane, Purushottam ;

Deshmukh, Rahul R. .

TRANSLATIONAL ONCOLOGY, 2020, 13 (03)

[4] Comprehensive molecular characterization of gastric adenocarcinoma [J].

Bass, Adam J. ;

Thorsson, Vesteinn ;

Shmulevich, Ilya ;

Reynolds, Sheila M. ;

Miller, Michael ;

Bernard, Brady ;

Hinoue, Toshinori ;

Laird, Peter W. ;

Curtis, Christina ;

Shen, Hui ;

Weisenberger, Daniel J. ;

Schultz, Nikolaus ;

Shen, Ronglai ;

Weinhold, Nils ;

Keiser, David P. ;

Bowlby, Reanne ;

Sipahimalani, Payal ;

Cherniack, Andrew D. ;

Getz, Gad ;

Liu, Yingchun ;

Noble, Michael S. ;

Pedamallu, Chandra ;

Sougnez, Carrie ;

Taylor-Weiner, Amaro ;

Akbani, Rehan ;

Lee, Ju-Seog ;

Liu, Wenbin ;

Mills, Gordon B. ;

Yang, Da ;

Zhang, Wei ;

Pantazi, Angeliki ;

Parfenov, Michael ;

Gulley, Margaret ;

Piazuelo, M. Blanca ;

Schneider, Barbara G. ;

Kim, Jihun ;

Boussioutas, Alex ;

Sheth, Margi ;

Demchok, John A. ;

Rabkin, Charles S. ;

Willis, Joseph E. ;

Ng, Sam ;

Garman, Katherine ;

Beer, David G. ;

Pennathur, Arjun ;

Raphael, Benjamin J. ;

Wu, Hsin-Ta ;

Odze, Robert ;

Kim, Hark K. ;

Bowen, Jay .

NATURE, 2014, 513 (7517) :202-209

[5] Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study [J].

Boku, N. ;

Ryu, M. H. ;

Oh, D-Y. ;

Oh, S. C. ;

Chung, H. C. ;

Lee, K-W. ;

Omori, T. ;

Shitara, K. ;

Sakuramoto, S. ;

Chung, I. J. ;

Yamaguchi, K. ;

Kato, K. ;

Sym, S. J. ;

Kadowaki, S. ;

Tsuji, K. ;

Chen, J-S. ;

Bai, L-Y. ;

Chen, L-T. ;

Kang, Y-K. .

ANNALS OF ONCOLOGY, 2020, 31 :S1192-S1192

[6] Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion [J].

Chaganty, Bharat K. R. ;

Qiu, Songbo ;

Gest, Anneliese ;

Lu, Yang ;

Ivan, Cristina ;

Calin, George A. ;

Weiner, Louis M. ;

Fan, Zhen .

CANCER LETTERS, 2018, 430 :47-56

[7] Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials [J].

Chao, Joseph ;

Fuchs, Charles S. ;

Shitara, Kohei ;

Tabernero, Josep ;

Muro, Kei ;

Van Cutsem, Eric ;

Bang, Yung-Jue ;

De Vita, Ferdinando ;

Landers, Gregory ;

Yen, Chia-Jui ;

Chau, Ian ;

Elme, Anneli ;

Lee, Jeeyun ;

Ozguroglu, Mustafa ;

Catenacci, Daniel ;

Yoon, Harry H. ;

Chen, Erluo ;

Adelberg, David ;

Shih, Chie-Schin ;

Shah, Sukrut ;

Bhagia, Pooja ;

Wainberg, Zev A. .

JAMA ONCOLOGY, 2021, 7 (06) :895-902

[8] First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811 [J].

Chung, Hyun Cheol ;

Bang, Yung-Jue ;

S Fuchs, Charles ;

Qin, Shu-Kui ;

Satoh, Taroh ;

Shitara, Kohei ;

Tabernero, Josep ;

van Cutsem, Eric ;

Alsina, Maria ;

Cao, Zhu Alexander ;

Lu, Jia ;

Bhagia, Pooja ;

Shih, Chie-Schin ;

Janjigian, Yelena Y. .

FUTURE ONCOLOGY, 2021, 17 (05) :491-501

[9] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[10] Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells [J].

Gall, Victor A. ;

Philips, Anne V. ;

Qiao, Na ;

Clise-Dwyer, Karen ;

Perakis, Alexander A. ;

Zhang, Mao ;

Clifton, Guy T. ;

Sukhumalchandra, Pariya ;

Ma, Qing ;

Reddy, Sangeetha M. ;

Yu, Dihua ;

Molldrem, Jeffrey J. ;

Peoples, George E. ;

Alatrash, Gheath ;

Mittendorf, Elizabeth A. .

CANCER RESEARCH, 2017, 77 (19) :5374-5383

← 1 2 3 4 →